Rare lephants

Screener

Altimmune, Inc.

ALT ·Healthcare, Drug Manufacturers - General, United States

Analysis
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation

Profit History
Revenue Breakdown
Profit Flow
Profit Margins
Returns on Capital

Profitability › Revenue Breakdown

← 5Y 10Y MAX →

Revenue Breakdown

Fiscal Year	Revenue
FY2021	$4.4M
FY2022	$-68.0K
FY2023	$426.0K
FY2024	$20.0K
FY2025	$41.0K

Rare lephants

Fundamental stock research — financial statements, interactive charts, a stock screener, valuation tools, and moat scoring, all in one place.

Support

If you find RareElephants useful, please consider donating to help pay hosting costs and keeping the site fee to use.

Product

Screener Valuation Tools Company Research Financial Statements Historical Fundamentals

Company

About Contact

Legal

Terms Privacy

© 2026 Rare Elephants. All data is provided for informational and educational purposes only — it is not investment, legal, or tax advice, and we make no guarantee of its accuracy or completeness. Always verify figures independently before making a decision.